PubMed HealthSearch

PubMed · 2192972

[Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine].

Abstract

We studied the effect of a single dose of the local carbonic anhydrase inhibitor, MK-927, on lowering IOP in 24 patients with bilateral primary open-angle glaucoma or ocular hypertension and compared it with the effect of pilocarpin in 9 patients. Following a washout of any glaucoma medication of 3 to 14 days, a diurnal IOP curve was performed. Two to seven days later one eye received a single drop of 2% MK-927 while the other eye received placebo and the diurnal IOP curve was repeated. MK-927 treated eyes showed a peak mean IOP change of 10.5 mmHg (33.1%) occurring at 4.5 h postmedication. In nine eyes treated with pilocarpin 1% q.d., the mean reduction of the mean IOP was 7.0 mmHg (22.1%) compared to no treatment. The same eyes showed a mean reduction of mean IOP of 6.1 mmHg (18.9%) following a single dose of MK-927. In contrast, the mean reduction of the maximal IOP treated with pilocarpin was 7.3 mmHg (25.8%) and 10.2 mmHg (34.2%) following MK-927. Considering the IOP lowering of MK-927 shown here, the possibility of a topically effective glaucoma therapy by local carbonic anhydrase inhibitor seems to be established. The IOP lowering effect of MK-927 appears to be similar to that of pilocarpin 1%.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N Pfeiffer, F Grehn, R Hennekes, H Garus. 1990. [Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine].. https://pubmed.ncbi.nlm.nih.gov/2192972/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The periodic paralyses.

These mysterious attacks of muscle weakness are difficult to treat because the different forms are hard to define, and potassium plays a different role in each one. New genetic probes should finally resolve these issues. In the meantime, attacks can be prevented in at least some patients. A multicenter study is now under way to determine the best treatment for each subtype.

Carbonic Anhydrase Inhibitors

Indirect chiral separation and analyses in human biological fluids of the stereoisomers of a thienothiopyran-2-sulfonamide (TRUSOPT), a novel carbonic anhydrase inhibitor with two chiral centers in the molecule.

The indirect chiral separation of the four stereoisomers (1)-(4) of a novel carbonic anhydrase inhibitor with two chiral centers in the molecule is reported. The method is based on chemical derivatization of the secondary amino group of the inhibitor with chiral isocyanate, formation of diastereomeric urea derivatives, each with three chiral centers in the molecule, and their separation under nonchiral HPLC conditions. The attempts to separate racemic mixture (1) + (2) from its diastereomeric counterpart (3) + (4) under nonchiral conditions, and to separate enantiomers (1) and (2) directly on a chiral stationary phase (CSP) are also reported. The indirect method was utilized for the assessment of an in vivo inversion of configuration at either one or both chiral centers of the molecule of (1). Analyses of selected whole blood and urine samples from human subjects after multiple bilateral topical ocular dosing with (1) did not reveal the presence of any of the three possible stereoisomers (2)-(4) of (1) indicating that the inversion of configuration at neither one nor two chiral centers of (1) occurs in vivo.

Carbonic Anhydrase Inhibitors